Fresenius Kabi starts work on $250m US sterile drug plant

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Manufacturing

Fresenius Kabi execs Steve Nowicki, Dr. Michael Schoenhofen and John Ducker join Mayor Ron Serpico of Melrose Park, Illinois at groundbreaking ceremony
Fresenius Kabi execs Steve Nowicki, Dr. Michael Schoenhofen and John Ducker join Mayor Ron Serpico of Melrose Park, Illinois at groundbreaking ceremony
Fresenius Kabi has started work on a $250m (€220m) sterile drug manufacturing plant in Illinois, US.

The German drug manufacturer announced plans for facility last year​, explaining that construction at the site in Chicago’s Melrose Park suburb will help it capture a greater share of the US injectables market.

The project will create several manufacturing suites equipped with automated aseptic filling lines, expanded lyophilization capabilities, and formulation areas, as well as a dedicated warehouse for raw materials.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us

Products

View more

Webinars